Phase 1 crossover trial in 72 healthy individuals: an oral suspension of netupitant/palonosetron (NEPA) was bioequivalent to the hard capsule, with AUC0-t ratios within 80-125% for both drugs; both formulations were well tolerated.
RCTn = 72
Gasanin et al. Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial